首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   212119篇
  免费   22019篇
  国内免费   13123篇
耳鼻咽喉   2355篇
儿科学   3012篇
妇产科学   2009篇
基础医学   18809篇
口腔科学   4015篇
临床医学   24960篇
内科学   25371篇
皮肤病学   2391篇
神经病学   8302篇
特种医学   8228篇
外国民族医学   87篇
外科学   21780篇
综合类   47070篇
一般理论   11篇
预防医学   17996篇
眼科学   4669篇
药学   23728篇
  341篇
中国医学   16984篇
肿瘤学   15143篇
  2024年   245篇
  2023年   2997篇
  2022年   5895篇
  2021年   9165篇
  2020年   9138篇
  2019年   9442篇
  2018年   5606篇
  2017年   6691篇
  2016年   5441篇
  2015年   9607篇
  2014年   12342篇
  2013年   12851篇
  2012年   18588篇
  2011年   19807篇
  2010年   15239篇
  2009年   12793篇
  2008年   14166篇
  2007年   13680篇
  2006年   12694篇
  2005年   10685篇
  2004年   7742篇
  2003年   7225篇
  2002年   6007篇
  2001年   4506篇
  2000年   3425篇
  1999年   2521篇
  1998年   1425篇
  1997年   1363篇
  1996年   1046篇
  1995年   959篇
  1994年   758篇
  1993年   471篇
  1992年   487篇
  1991年   392篇
  1990年   375篇
  1989年   273篇
  1988年   235篇
  1987年   218篇
  1986年   166篇
  1985年   121篇
  1984年   66篇
  1983年   49篇
  1982年   33篇
  1981年   39篇
  1980年   22篇
  1979年   43篇
  1977年   19篇
  1976年   17篇
  1974年   22篇
  1973年   28篇
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
1.
2.
3.
Whether ultra-processed food consumption is associated with the risk of pancreatic cancer has not been determined. We performed a prospective study to fill this gap. A population-based cohort of 98 265 American adults was identified from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Ultra-processed foods were defined by the NOVA classification. Cox regression was used to estimate hazard ratios (HRs) for pancreatic cancer incidence. Subgroup analysis was performed to identify the potential effect modifiers. During a mean follow-up of 8.86 years, 387 pancreatic cancer cases occurred. High consumption of ultra-processed foods was found to be associated with an increased risk of pancreatic cancer (fully adjusted HRquartile 4 vs 1:1.49; 95% confidence interval [CI]: 1.07-2.07; Ptrend = .021) in a linear dose-response manner (Pnonlinearity = .075). Subgroup analysis further found that the positive association of ultra-processed food consumption with the risk of pancreatic cancer was more pronounced in subjects aged <65 years (HRquartile 4 vs 1:2.17; 95% CI: 1.14-4.15) than in those aged ≥65 years (HRquartile 4 vs 1:1.32; 95% CI: 0.88-1.94), though the interaction test failed to achieve the statistical significance (Pinteraction = .061). These findings suggest that reducing ultra-processed food consumption may be beneficial in decreasing pancreatic cancer incidence.  相似文献   
4.
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC.  相似文献   
5.
We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177).  相似文献   
6.
Formal multidisciplinary team (MDT) discussions in clinical practice require time and space but have unclear survival benefits for advanced gastrointestinal cancer patients. Our study aimed to investigate the long-term survival of patients with advanced gastrointestinal cancer after MDT decision. From June 2017 to June 2019, continuous MDT discussions on advanced gastrointestinal cancer were conducted in 13 medical centers in China. MDT decisions and actual treatment received by patients were prospectively recorded. The primary endpoint was the difference in overall survival (OS) between patients in the MDT decision implementation and nonimplementation groups. The secondary endpoints included the implementation rate of MDT decisions and subgroup survival analysis. A total of 461 MDT decisions of 455 patients were included in our study. The implementation rate of MDT decisions was 85.7%. Previous treatment had an impact on MDT decision-making. The OS was 24.0 months and 17.0 months in the implementation and nonimplementation groups, respectively. The implementation of MDT decisions significantly reduced the risk of death in multivariate analyses (hazard ratio = 0.518; 95% confidence interval: 0.304-0.884, P = .016). Subgroup analysis showed a significant difference in survival of patients with colorectal cancer, but not in survival of patients with gastric cancer. The rate of secondary MDT discussion was only 5.6% among patients who the MDT decisions were discontinued due to changes in their condition. MDT discussion can prolong the OS of patients with advanced gastrointestinal cancer, especially those with colorectal cancer. Timely scheduling of the subsequent MDT discussion is necessary when the disease condition changes.  相似文献   
7.
8.
既往左心耳内血栓是左心耳封堵的禁忌证。该文报道1例心房颤动患者, 有反复脑梗死病史, 合并糖尿病、肾功能不全及冠心病, 心脏CT血管成像诊断左心耳血栓, 因抗凝治疗不耐受, 故行左心耳封堵术。术后予抗凝和/或抗血小板治疗仍反复发生器械相关血栓。提示心房颤动合并左心耳血栓患者应慎行左心耳封堵术, 术后需个体化调整抗栓方案、密切随诊。  相似文献   
9.
目的研究老年人群无症状脑小血管病(CSVD)的发生率、影像学特征及其影响因素。方法选取2019年10月至2020年8月在我院老年医学部门诊体检、既往无神经系统疾病病史的老年人共201例, 完善头颅磁共振成像(MRI)检查。采用脑小血管病总负担评分对腔隙灶、脑白质病变、脑微出血及血管周围间隙扩大共4种CSVD影像学特征进行总体评估, 记为0~4分。分析入组人群不同影像学特征分布情况, 并将CSVD总负担评分与其临床情况进行相关性分析。结果本研究中影像学符合CSVD共133例(66.2%)。其中, 腔隙灶44例(21.9%), 中-重度脑室旁白质病变(PVWMH)88例(43.8%), 中-重度深部脑白质病变(DWMH)30例(14.9%), 基底节区血管周围间隙扩大(EPVS)61例(30.3%), 脑微出血(CMB)92例(45.8%)。CSVD总负担评分(OR=1.876, 95%CI:1.045~3.364, χ2=4.441, P=0.035)、PVWMH(OR=2.821, 95%CI:1.517~5.244, χ2=10.752, P=0.001)、DWMH(OR=2.130...  相似文献   
10.
Metabolic Brain Disease - Doxorubicin (DOX) is an effective anticancer drug, however, side effects such as cognitive impairment and cardiotoxicity have limited its clinical use. Juglanin (JUG) is a...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号